High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus
- PMID: 17581626
- PMCID: PMC2702174
- DOI: 10.1038/sj.gene.6364408
High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus
Abstract
Interferon alpha (IFN-alpha) levels are elevated in many patients with systemic lupus erythematosus (SLE); however it is not known whether high serum IFN-alpha activity is a cause or a result of the disease. We studied 266 SLE patients and 405 of their healthy relatives, and frequently found high serum IFN-alpha activity in both patients and healthy relatives as compared to healthy unrelated individuals. High IFN-alpha activity was clustered in specific families in both SLE patients and their healthy first-degree relatives, suggesting a heritable trait. Heritability was also supported by quantitative familial correlation of IFN-alpha activity, concordance in affected sib pairs and frequent transmission of the high IFN-alpha activity trait from parents to offspring. Autoantibodies to RNA-binding proteins and double-stranded DNA were associated with high IFN-alpha activity in SLE patients; however these autoantibodies were very uncommon in healthy family members and did not explain the observed familial correlations. The frequency of high IFN-alpha activity was similar across all studied ethnic backgrounds. These data suggest that high serum IFN-alpha activity is a complex heritable trait, which plays a primary role in SLE pathogenesis.
Figures





Similar articles
-
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus.Ann Rheum Dis. 2012 Mar;71(3):463-8. doi: 10.1136/annrheumdis-2011-200463. Epub 2011 Nov 16. Ann Rheum Dis. 2012. PMID: 22088620 Free PMC article.
-
Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.Ann Rheum Dis. 2016 Nov;75(11):2014-2021. doi: 10.1136/annrheumdis-2015-208140. Epub 2016 Jan 25. Ann Rheum Dis. 2016. PMID: 27088255 Free PMC article.
-
Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse.Ann Rheum Dis. 2019 Dec;78(12):1669-1676. doi: 10.1136/annrheumdis-2019-215571. Epub 2019 Sep 30. Ann Rheum Dis. 2019. PMID: 31570366
-
Interferon alpha as a primary pathogenic factor in human lupus.J Interferon Cytokine Res. 2011 Dec;31(12):887-92. doi: 10.1089/jir.2011.0071. Epub 2011 Sep 16. J Interferon Cytokine Res. 2011. PMID: 21923413 Free PMC article. Review.
-
Interferon regulatory factors in human lupus pathogenesis.Transl Res. 2011 Jun;157(6):326-31. doi: 10.1016/j.trsl.2011.01.006. Epub 2011 Feb 8. Transl Res. 2011. PMID: 21575916 Free PMC article. Review.
Cited by
-
Advances in lupus genetics.Curr Opin Rheumatol. 2015 Sep;27(5):440-7. doi: 10.1097/BOR.0000000000000205. Curr Opin Rheumatol. 2015. PMID: 26218512 Free PMC article. Review.
-
Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus.Arthritis Res Ther. 2010;12(4):R151. doi: 10.1186/ar3101. Epub 2010 Jul 26. Arthritis Res Ther. 2010. PMID: 20659327 Free PMC article.
-
Promoter variant of PIK3C3 is associated with autoimmunity against Ro and Sm epitopes in African-American lupus patients.J Biomed Biotechnol. 2010;2010:826434. doi: 10.1155/2010/826434. Epub 2010 Jul 4. J Biomed Biotechnol. 2010. PMID: 20671926 Free PMC article.
-
Developments in the clinical understanding of lupus.Arthritis Res Ther. 2009;11(5):245. doi: 10.1186/ar2762. Epub 2009 Oct 14. Arthritis Res Ther. 2009. PMID: 19849817 Free PMC article. Review.
-
Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside.Int J Mol Sci. 2022 Feb 24;23(5):2505. doi: 10.3390/ijms23052505. Int J Mol Sci. 2022. PMID: 35269647 Free PMC article. Review.
References
-
- Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science. 2001;294:1540–1543. - PubMed
-
- Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52:1491–1503. - PubMed
-
- Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med. 1990;227:207–210. - PubMed
-
- Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-α therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol. 2005;24:178–181. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical